PET Insert for Preclinical PET-MRI

项目摘要 我们建议购买一种新的与Cubresa MRI兼容的PET插入物，以与我们的 凯斯西储大学现有9.4T Bruker Biospec临床前核磁共振扫描仪 (CWRU)。这种新的PET插入物将在克利夫兰创造第一个临床前PET-MRI能力， 将有效地协同我们广泛的临床前PET和MRI成像研究计划，以 支持25个主要用户在正电子发射计算机断层扫描和磁共振成像技术开发领域的研究， 分子显像剂、新的基因编辑策略、新陈代谢、炎症和 免疫学。有了这种新的PET-MRI功能，这些研究人员将能够将 高空间分辨率和宽范围的3D PET成像的无与伦比的灵敏度 MRI提供可选择的软组织对比。拟议的系统还将导致 显著降低成像成本和固有的3D PET-MRI图像联合配准 与序列PET-CT和MRI的比较。拟议的系统还将包括：1)PET- 优化的射频线圈可实现高灵敏度的MRI信号检测；2)呼吸门控 限制运动伪影；3)多个VivoQuant软件许可证，提供高效图像 可视化和分析；以及4)必要的生理监测和控制能力 有效的代谢成像研究。这些能力将广泛地惠及跨学科 调查小组的最终目标是改善癌症患者的医疗保健， 遗传性疾病包括囊性纤维化、炎症性肠病、神经退行性变 阿尔茨海默氏症和多发性硬化症、心血管疾病、糖尿病、 还有中风。这种新的临床前PET-MRI能力将适用于所有地区性研究人员 将由CWRU的成像研究核心运营，CWRU是 CWRU的多个研究中心，包括病例综合癌症中心(NCI P30 消化疾病研究核心中心(NIDDK P30 DK097948)，临床 和翻译科学合作(NCATS UL1 TR002548)，和囊性纤维化 研究中心。这项对成像研究核心的持续支持是对直接 机构支持100,000美元，以部分抵消这种新的PET成像插入物的成本。一个 咨询委员会，由CWRU和外部具有丰富经验的PET和MRI教师组成 各机构将监督该系统的组织和使用，并建议政策以 维护系统性能并最大化利用率。

Project Summary We propose to purchase a new Cubresa MRI-Compatible PET insert to be combined with our existing 9.4T Bruker Biospec preclinical MRI scanner at Case Western Reserve University (CWRU). This new PET insert will create the first preclinical PET-MRI capability in Cleveland that will efficiently synergize our extensive preclinical PET and MRI imaging research programs to support 25 major users with research in the areas of PET and MRI technology developments, molecular imaging agents, new gene editing strategies, metabolism, inflammation, and immunology. With this new PET-MRI capability, these investigators will be able to combine the unmatched sensitivity of 3D PET imaging with the high spatial resolution and wide range of selectable soft tissue contrasts provided by MRI. The proposed system will also result in significantly reduced imaging costs and inherent 3D PET-MRI image co-registration in comparison to sequential PET-CT and MRI. The proposed system will also include: 1) PET- optimized radiofrequency coils enabling high-sensitivity MRI signal detection; 2) respiratory gating to limit motion artifacts; 3) multiple VivoQuant software licenses to provide efficient image visualization and analysis; and 4) physiologic monitoring and control capabilities necessary for effective metabolic imaging studies. These capabilities will broadly benefit an interdisciplinary group of investigators with the ultimate goal of improving health care for patients with cancer, genetic diseases including cystic fibrosis, inflammatory bowel disease, neurodegenerative diseases such as Alzheimer’s Disease and multiple sclerosis, cardiovascular disease, diabetes, and stroke. This new preclinical PET-MRI capability will be available to all regional investigators and will be operated by the Imaging Research Core at CWRU which is an integral component of multiple research centers at CWRU including the Case Comprehensive Cancer Center (NCI P30 CA043703), the Digestive Diseases Research Core Center (NIDDK P30 DK097948), the Clinical and Translational Science Collaborative (NCATS UL1 TR002548), and the Cystic Fibrosis Research Center. This ongoing support for the Imaging Research Core is in addition to the direct institutional support of $100,000 to partially offset the cost for this new PET imaging insert. An advisory committee with highly experienced PET and MRI faculty at CWRU and external institutions will oversee the organization and usage of the system and recommend policies to maintain system performance and maximize utilization.